Recruiting
Phase 1

PF-08049820 with Rabeprazole

Sponsor:

Pfizer

Code:

NCT07597928

Conditions

Healthy Adults

Healthy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

PF-08049820

Rabeprazole

Study Details

Brief summary:

The purpose of this study is to learn how different forms of the study medicine called PF-08049820 are absorbed and eliminated in healthy adults. The study will assess whether the study medicine is absorbed differently when taken with or without food. It will also assess absorption when the study medicine is taken with another medicine called rabeprazole. Rabeprazole is an FDA approved medicine that reduces stomach acid.

The study has two parts. In Part A, participants will take three forms of study medicine, one after the other. They will take each form either with or without food for a total of five doses. Each dose will be separated by a few days. Participants will stay in the clinic for about two weeks. They will receive a telephone follow-up call about a month after the last dose.

In Part B, participants will take three forms of study medicine. They will take each one with or without food, and with or without another medicine called rabeprazole. This means they will take a total of six doses of study medicine. Each dose will be separated by a few days. Participants will stay at the clinic for about three weeks, and about a month after their last dose. They will get a follow-up phone call. Part B may or may not be conducted depending on the results from Part A.

The study is seeking participants who:

1. Are males or females,
2. Are at least 18 years of age,
3. Have a body mass index (BMI) 16 to 32 kilograms per meter squared (kg/m2). Have a total body weight of more than 50 kilograms (kg) (110 pounds).

Conditions

Healthy Adults

Healthy

Study ID

NCT07597928

Start date

May 13, 2026

Status verified date

Jun, 2026

Completion date

Sep 25, 2026

Anticipated

Primary completion date

Sep 3, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Healthy males and females.
2. At least 18 years of age
3. Body mass index (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.).

Exclusion Criteria:

1. Evidence or history of clinically significant medical conditions.
2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B or hepatitis C.
3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
4. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

Study Design

Enrollment

24 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Sequence 1 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 2 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 3 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 4 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 5 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 6 (Part A)

3 different formulations of PF-08049820 administered orally under fasted or fed conditions.

experimental: Sequence 7 (Optional Part B)

3 different formulations of PF-08049820 administered orally with or without rabeprazole under fasted or fed conditions.

Interventions

PF-08049820

Administered orally

Rabeprazole

Administered orally

Primary outcome measure

  • Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) [ Time Frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B ]
  • Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit [ Time Frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B ]
  • Maximum observed plasma concentration (Cmax) [ Time Frame: Baseline up to Day 16 for Part A and up to Day 24 for optional Part B ]

Central Contacts and Locations

Central contacts

Locations

Pfizer Clinical Research Unit - New Haven

Recruiting

New Haven, Connecticut, United States, 06511

More Information

Sponsor

Pfizer

Last update posted

Jun 15, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Pfizer on 2026-06-15.